Physician profile
Benjamin D Keeley
NPI 1881694545
$6,752.99
in general payments reported to CMS, 2019-2025
47 companies · $1,130 in 2025
The $1,130 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,279 · 2020: $555 · 2021: $847 · 2022: $932 · 2023: $1,208 · 2024: $801 · 2025: $1,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,139.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,049.45 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $687.67 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $659.48 | 2019-2025 | |
| Abbvie INC. | $645.75 | 2021-2025 | |
| Amarin Pharma, INC. | $422.46 | 2019-2021 | |
| Amgen INC. | $316.37 | 2019-2025 | Repatha, Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $236.03 | 2022-2025 | Rexulti, Nuedexta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $209.76 | 2019-2025 | Xifaxan |
| Exact Sciences Corporation | $171.15 | 2023-2025 | Cologuard Collection Kit |
| Avanir Pharmaceuticals, INC. | $160.22 | 2019-2022 | |
| Glaxosmithkline, LLC. | $152.82 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astellas Pharma US INC | $139.78 | 2019-2023 | Myrbetriq |
| Sunovion Pharmaceuticals INC. | $138.17 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $133.44 | 2023-2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.91 | 2019-2024 | Jardiance |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Keeley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.